Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Oct 8 · below the Ichimoku cloud · RSI 57 · MACD above its signal
None of the 29 investors followed here reported a position in RZLT in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RZLT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 29, 2026 | Evans DaronChief Financial Officer | Purchase at price 2.85 per share. | 10K | $28.50K |
| Dec 15, 2025 | Hogenhuis WladimirDirector | Purchase at price 1.69 per share. | 5.7K | $9.55K |
| Dec 15, 2025 | Roberts Brian KennethOfficer | Purchase at price 1.70 per share. | 28K | $47.60K |
| Dec 14, 2025 | Karnawat Sunil RatilalOfficer | Purchase at price 1.60 - 1.62 per share. | 12.1K | $19.60K |
| Dec 14, 2025 | Elam Nevan CChief Executive Officer | Purchase at price 1.59 per share. | 32K | $50.88K |
| Dec 14, 2025 | Evans DaronChief Financial Officer | Purchase at price 1.77 - 1.79 per share. | 45K | $79.58K |
| Nov 18, 2025 | Karnawat Sunil RatilalOfficer | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Nov 18, 2025 | Elam Nevan CChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 317K | — |
| Nov 18, 2025 | Labrucherie Gilbert M JrDirector | Stock Award(Grant) at price 0.00 per share. | 21K | — |
| Nov 18, 2025 | Evans DaronChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 107K | — |
| Nov 18, 2025 | Kreher Nerissa CDirector | Stock Award(Grant) at price 0.00 per share. | 21K | — |
| Nov 18, 2025 | Hogenhuis WladimirDirector | Stock Award(Grant) at price 0.00 per share. | 21K | — |
| Nov 18, 2025 | Kim Young-JinDirector | Stock Award(Grant) at price 0.00 per share. | 21K | — |
| Nov 18, 2025 | Harris ErikDirector | Stock Award(Grant) at price 0.00 per share. | 21K | — |
| Nov 18, 2025 | Fauchet PhilippeDirector | Stock Award(Grant) at price 0.00 per share. | 21K | — |
| Nov 18, 2025 | Roberts Brian KennethOfficer | Stock Award(Grant) at price 0.00 per share. | 123K | — |
| Aug 17, 2025 | Karnawat Sunil RatilalOfficer | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jun 24, 2025 | Roberts Brian KennethOfficer | Purchase at price 4.38 per share. | 2.5K | $10.94K |
| Jun 23, 2025 | Evans DaronChief Financial Officer | Purchase at price 4.05 per share. | 5K | $20.25K |
| Jun 12, 2025 | Kreher Nerissa CDirector | Purchase at price 4.20 per share. | 3.1K | $12.92K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 41.5 | -3.9 | -5.0 | 4.9 | 3.1 | 57.6 | -9.2 | -0.6 | -11.7 | 11.4 | +95.3% | ||
| 2025 | 7.1 | -15.6 | -34.5 | 29.7 | 9.6 | 8.3 | 33.4 | 19.7 | 32.0 | -0.9 | 4.3 | -75.7 | −51.8% |
| 2024 | 10.8 | 50.0 | 54.5 | 5.1 | 50.4 | 6.7 | 6.9 | 3.6 | 1.9 | 13.0 | -8.0 | -2.8 | +393.5% |
| 2023 | 24.2 | -3.5 | -22.6 | 8.6 | 2.2 | -7.0 | -5.6 | -23.0 | -8.3 | -28.0 | -18.7 | 28.6 | −52.0% |
| 2022 | -4.6 | -42.8 | 29.5 | 12.4 | -26.3 | 15.4 | -3.1 | -24.0 | 15.1 | -38.3 | -2.4 | 25.5 | −56.7% |
| 2021 | 33.2 | -28.0 | -38.6 | -5.1 | 54.2 | 38.1 | -22.0 | -17.0 | -19.1 | -14.4 | -20.6 | -5.9 | −60.1% |
| 2020 | 20.9 | -33.8 | -23.9 | 7.1 | -5.3 | 31.0 | 269.9 | 37.2 | -8.7 | 9.0 | -14.9 | -40.1 | +108.5% |
| 2019 | 166.7 | 25.0 | -33.3 | -10.5 | -21.8 | 41.4 | 7.1 | -10.4 | -21.1 | -14.0 | 93.8 | -54.0 | +27.8% |
| 2018 | -9.6 | -26.3 | -23.4 | 28.3 | -20.0 | -3.0 | -15.6 | 5.3 | -12.5 | -55.7 | -9.7 | -35.7 | −89.8% |
| 2017 | -0.5 | 5.5 | -4.8 | 5.0 | 9.5 | -1.7 | -2.7 | 4.5 | -13.0 | 0.0 | -5.0 | -6.8 | −11.5% |
| 2016 | -11.0 | -11.5 | 2.6 | -17.8 | -5.2 | 8.7 | 2.0 | -11.8 | 50.0 | -11.1 | 15.8 | -28.1 | −31.5% |
| 2015 | 32.8 | 35.5 | 0.0 | -17.8 | -2.2 | 7.7 | -4.6 | -14.0 | -9.4 | -11.7 | 21.1 | -5.8 | +16.8% |
| 2014 | 3.6 | 9.3 | -3.3 | 0.0 | 0.6 | -22.0 | -18.7 | -18.9 | -8.3 | -12.1 | 3.4 | -16.7 | −60.7% |
| 2013 | -20.0 | -12.5 | -28.6 | -15.0 | -9.9 | -15.3 | 44.8 | -36.2 | -25.0 | -33.3 | 76.7 | −73.5% |
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Buy / hold / sell counts